No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CDMO240719C5000
- 3.50
- +0.20+6.06%
15min DelayClose Jul 12 16:00 ET
3.50High3.50Low
3.50Open3.30Pre Close10 Volume510 Open Interest5.00Strike Price3.50KTurnover206.13%IV2.16%PremiumJul 19, 2024Expiry Date3.32Intrinsic Value100Multiplier6DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.9745Delta0.0254Gamma2.48Leverage Ratio-0.0100Theta0.0009Rho2.42Eff Leverage0.0007Vega
Intraday
- 5D
- Daily
News
KeyBanc Maintains Avid Bioservices(CDMO.US) With Buy Rating, Maintains Target Price $14
KeyBanc analyst Paul Knight maintains $Avid Bioservices(CDMO.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 42.1% and a tot
Why Avid Bioservices Stock Is Moving Higher Wednesday
Avid Bioservices, Inc. (NASDAQ:CDMO) shares are trading higher on Wednesday following the company reporting better-than-expected 2024 fiscal-year fourth quarter sales.The Details: Avid reported fourth
Avid Bioservices Shares Rise on Upbeat FY25 Outlook
By Michael Susin Avid Bioservices shares rose on Wednesday after the group said it expects revenue to sharply increase in fiscal 2025 and to generate positive cashflow and despite posting a widened f
Avid Bioservices Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 19.4% RBC Capital $8 → $8 Reiterates Outperform → Outperform 04/30/2024 19.4% RBC Capital $7 →
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating, Announces Target Price $16
Craig-Hallum analyst Matt Hewitt maintains $Avid Bioservices(CDMO.US)$ with a buy rating, and sets the target price at $16.According to TipRanks data, the analyst has a success rate of 39.4% and a tot
RBC Capital Maintains Avid Bioservices(CDMO.US) With Buy Rating, Maintains Target Price $8
RBC Capital analyst Sean Dodge maintains $Avid Bioservices(CDMO.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 39.2% and a t
Comments
Investors' belief in Societal CDMO's lackluster revenue performance not improving may be causing its low P/S ratio. The company's inferior revenue outlook compared to the industry average contributes to this. A significant change in fortune is needed to justify a higher P/S.
1
The company's high debt and lack of profitability strain its balance sheet. Negative free cash flow adds risk, but its US$417.4m market cap could potentially allow capital raising to strengthen the balance sheet.
Investors' belief in Avid Bioservices' stagnant revenue performance and future growth lagging behind the industry has led to its low P/S. The underwhelming revenue outlook and shareholders' pessimism impact the P/S negatively.
Despite good revenue growth, the market expected more, as seen in the share price drop. This could hint at delayed revenue growth. The recent sell-off might be an investment chance considering the signs of a continued growth trend.
Read more